Form 1095

Halfpricesoft.com Offers Support For ez1095 Software Last Minute Filing Questions For Clients

Retrieved on: 
Wednesday, February 28, 2024
Panic, ACA, Form 1095, SSA, IRS, Software

BALTIMORE, Md., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Halfpricesoft.com staff is dedicating extended support for clients rushing to get ACA forms 1095 and 1094 IRS copies completed before the Feb 28, 2024 deadline (for paper filers). Customers need not panic as the customer support team is on standby to answer questions on the software, help with questions on the processing of forms or any other inquiries on the ez1095 ACA software offered to help streamline the tasks at hand.

Key Points: 
  • Customers need not panic as the customer support team is on standby to answer questions on the software, help with questions on the processing of forms or any other inquiries on the ez1095 ACA software offered to help streamline the tasks at hand.
  • Halfpricesoft.com offers extended customer support for clients with questions with 2023 ez1095 for upcoming deadlines.
  • "Halfpricesoft.com offers customer support for clients with questions with 2023 ez1095 for upcoming deadlines."
  • ez1095 starts at $295.00 for a single user print version (395.00 for single user efile version) Test drive the latest ez1095 ACA software at no cost or obligation at: https://www.halfpricesoft.com/aca-1095/aca-1095-software.asp

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

Retrieved on: 
Thursday, February 15, 2024
Community health, Form 1095, AstraZeneca, ICR, CMS, Food, Growth, NGS, Risk, Risk assessment, Food and Drug Administration, Patient, Journal, Kidney disease, Kidney, LCD, Prescription, Research, Pharmaceutical industry

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023.

Key Points: 
  • LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023.
  • The Company plans to issue another announcement following today’s report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
  • Total billable volume of 734 tests during the second quarter (representing 69% of all tests in the period, including non-billable study tests).
  • Operating cost reductions commenced during the fiscal second quarter continued with a fiscal third quarter cash burn target approximately 33% less than in the prior quarter and approximately 50% less than in the first quarter of fiscal 2024.

Kidney Patients Target Medicare Transplant Double Standard

Retrieved on: 
Friday, February 9, 2024
Kidney failure, Family, Congress, Callous, Kidney transplantation, Form 1095, Society, The Wall Street Journal, LCD, ASTS, HHS, Kidney disease, Anxiety, Bleeding, Life, Infection, Biopsy, Congressional Black Caucus, Health equity, Insurance, Social media, History, Diagnosis, Health, Patient, House, Policy, Language, CMS, Kidney, RealClearPolitics, FMLA, Organ transplantation, Editorial, Pelvic floor dysfunction, Empathy, Death, Pharmaceutical industry

WASHINGTON, Feb. 9, 2024 /PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest kidney patient organization in the nation, issued an Official Statement (appears below) and an AAKP Closer Look report highlighting a new, double standard and unequal access for Medicare kidney transplant recipients who rely upon molecular blood tests for organ health surveillance and the identification of early organ rejection. Kidney disease and kidney failure disproportionately impact minority Americans. Federal data consistently demonstrates that, among historically disadvantaged communities, there are tremendous barriers and lack of opportunity to receive a kidney transplant and furthermore, re-transplantation when a donor organ fails.

Key Points: 
  • The new restrictions severely limit Medicare patients and transplant professionals from accessing molecular blood tests, covered by Medicare and utilized since 2017.
  • It is absolutely clear this is a new double standard for Medicare transplant recipients.
  • Today, Medicare patients with a kidney transplant in South Carolina and across the nation face the new reality of unequal treatment to protect their precious gifts of life.
  • Their failed leadership has empowered unelected, unaccountable, and faceless for-profit contractors to make life and death decisions that negatively impact kidney transplant patients on Medicare.

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Retrieved on: 
Tuesday, January 16, 2024
Research, Medical Devices, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, MSI, LCD, Patient, Form 1095, PSNL, DNA, Medicare, RNA, DX, TMB, Genomics, NeXT, Transcriptome, Microsatellite instability, FDA, Biomarker, Palmetto, Clinical trial, Physician, Health insurance

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.
  • Matching patients to their optimal cancer therapy requires a testing platform that can accurately report a broader range of clinically actionable genomic alterations.
  • Coverage for NeXT DX was extended effective August 29, 2023, under the Palmetto GBA MolDx program foundational Local Coverage Determination (LCD) L38119 (“Next-Generation Sequencing for Solid Tumors”).
  • Personalis estimates that approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare.

Dignitana Announces Palmetto GBA Approves First Local Coverage Determination for Scalp Cooling Therapy

Retrieved on: 
Tuesday, October 3, 2023
Form 1095, Manual, CMS, Final, Education, Hypothermia, London, Billing, Food and Drug Administration, Scalp, Part, Category, LCD, Pub, NCD, Chapter One, MACS, MAC, CIA, Patient, AMA, FDA, Food, Pharmaceutical industry, Health insurance, Palmetto, Medicare

LUND, Sweden, Oct. 3, 2023 /PRNewswire/ -- Dignitana announces that the Palmetto GBA Medicare Administrative Contractor (MAC) has issued a Local Coverage Determination (LCD) to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia.

Key Points: 
  • LUND, Sweden, Oct. 3, 2023 /PRNewswire/ -- Dignitana announces that the Palmetto GBA Medicare Administrative Contractor (MAC) has issued a Local Coverage Determination (LCD) to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia.
  • This is the first LCD that has been approved for scalp cooling and is a result of a request made to Palmetto GBA in February 2023 by Dignitana and Paxman.
  • In the Billing and Coding Guide: Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia , Palmetto GBA reaffirms guidance from CMS, "CMS Internet-Only Manual, Pub.
  • This action solidifying localized coverage further advances support for healthcare providers to receive reimbursement from Medicare to administer FDA-cleared scalp cooling therapy, such as The DigniCap Scalp Cooling System.

CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection

Retrieved on: 
Friday, August 11, 2023
Biotechnology, General Health, Surgery, Health, Health Technology, Heart, DNA, Form 1095, CMS, LCD, Gene expression profiling, Lung, Medicare, Patient, Medicine, Kidney, Caregiver, Pharmaceutical industry

CareDx is pleased that MolDX is providing the public with the opportunity to participate in an open and transparent process, as advocated by CareDx and many others across the transplant community.

Key Points: 
  • CareDx is pleased that MolDX is providing the public with the opportunity to participate in an open and transparent process, as advocated by CareDx and many others across the transplant community.
  • CareDx will continue to review the proposed LCD and looks forward to providing comments on the draft policy.
  • This has created unnecessary clinician confusion, chaos, and disruption to patient care,” said Reg Seeto, CEO and President of CareDx.
  • CareDx has invested hundreds of millions of dollars and over two decades to support the transplant community, leading with innovation.

Relievant Medsystems Announces Favorable Coverage Policy from Cigna Healthcare for the Intracept Procedure

Retrieved on: 
Tuesday, June 20, 2023
Insurance, Form 1095, Short-term energy-relieving behavior, Brain, Inflammation, Cigna, LCD, Pain, Medicare, DO, MAC, Vertebra, Patient, BVN, Diagnosis, FDA, Health insurance, Medical imaging

MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced today that Cigna Healthcare, a health benefits provider for 19 million Americans, has established national coverage for the Intracept® Procedure.

Key Points: 
  • MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced today that Cigna Healthcare, a health benefits provider for 19 million Americans, has established national coverage for the Intracept® Procedure.
  • “This positive coverage determination from Cigna Healthcare, one of the country’s leading health benefit providers, is vastly impactful in increasing patient and physician access to our proven treatment for vertebrogenic pain,” said Tyler Binney, President and CEO of Relievant Medsystems.
  • More than 10,000 patients have now been treated with Relievant Medsystems’ minimally invasive Intracept Procedure, the only FDA-cleared treatment for chronic vertebrogenic low back pain.
  • The Intracept Procedure is supported by strong scientific evidence, including two Level I randomized clinical trials and data showing improvements are sustained more than five years post-procedure.

Dignitana announces proposal for Local Coverage Determination of scalp cooling therapy

Retrieved on: 
Thursday, June 15, 2023
Contraindication, Form 1095, CMS, Education, Centers for Medicare & Medicaid Services, London, Scalp, LCD, Draft, MAC, Patient, Physician, AMA, FDA, Macs, Health insurance, Pharmaceutical industry, Palmetto, Medicare

LUND, Sweden, June 15, 2023 /PRNewswire/ -- Dignitana announces that the Palmetto Medicare Administrative Contractor (MAC) has issued a Proposed Local Coverage Determination (LCD) to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia.

Key Points: 
  • LUND, Sweden, June 15, 2023 /PRNewswire/ -- Dignitana announces that the Palmetto Medicare Administrative Contractor (MAC) has issued a Proposed Local Coverage Determination (LCD) to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia.
  • This is the first LCD that has been proposed for scalp cooling.
  • This action proposing localized coverage further advances support for health care providers to receive reimbursement from Medicare to administer FDA-cleared scalp cooling therapy, such as The DigniCap Scalp Cooling System.®  Two separate CPT® Category III Codes for "mechanical scalp cooling," 0662T and 0663T, were issued by the AMA with an effective date of July 1, 2021.
  • The CPT® codes, coupled with coverage determinations such as the proposed LCD, will expand patient access to scalp cooling and enable oncology providers to appropriately offer the service and bill for the resources required to administer scalp cooling therapy.

Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Retrieved on: 
Monday, June 5, 2023
Pancreatic cancer, Form 1095, CMS, Centers for Medicare & Medicaid Services, CEA, Glucose, Novita, Genetic testing, LCD, Medicare, MAC, Patient, Physician, Risk, Disease, Diagnosis, Mortality, Pancreatic cyst, Franciscan Ceramics, Pharmaceutical industry

The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results.

Key Points: 
  • The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results.
  • For the past decade, CMS has provided reimbursement for PancraGEN, and over that time nearly 70,000 patients have been tested on orders from physicians across the country.
  • We are extremely disappointed that CMS, through its Medicare Administrative Contractor (MAC), Novitas, is ending coverage for PancraGEN—an important and widely utilized test.
  • Yet, studies have shown that 60% to 80% of surgeries reveal indolent cysts that did not necessarily require surgery.

Foundational LCD Covers Select mdx for Prostate Cancer

Retrieved on: 
Wednesday, April 19, 2023
Form 1095, Risk, Prostate cancer, Genomics, Marker beacon, LCD, NCCN, Medicare, Patient, Urology, Medical imaging, Pharmaceutical industry, Select

IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA.
  • Select mdx will be reimbursed throughout the U.S. for Medicare patients who meet coverage conditions under the foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer.
  • We look forward to expanding the availability of our test to current and new customers and to patients entering the diagnostic pathway of prostate cancer.
  • We believe our pre-biopsy Select mdx test, coupled with our post-biopsy Confirm mdx® and Genomic Prostate Score (formerly Oncotype DX GPS) tests, provides the most comprehensive and clinically actionable pathway for urologists and patients.”